Company family
Avansor: medicine shortages
As of 2 Nov 2026, 13 Avansor products have a reported shortage across 1 countries, covering 6 medicines.
Products short13rank #148 of 464
Medicines6active ingredients
Countries1/16
New in 90 days0-2 vs market pace
Typical duration3.4 yearsmedian so far
Manufacturing0%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Lenalidomide | 5 | 12 Dec 2022 | Not stated | 10/16 | |
| Pomalidomide | 3 | 23 Dec 2025 | Not stated | 6/16 | |
| Sunitinib | 2 | 26 Jun 2023 | Not stated | 5/16 | |
| Abiraterone | 1 | 22 Feb 2023 | Not stated | 7/16 | |
| Everolimus | 1 | 20 Jul 2026 | Not stated | 3/16 | |
| Icatibant | 1 | 24 Dec 2025 | Not stated | 8/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.